633 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by GSA Capital Partners LLP

GSA Capital Partners LLP purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 3rd quarter, Holdings Channel reports. The fund purchased 633 shares of the biopharmaceutical company’s stock, valued at approximately $665,000.

Other institutional investors also recently added to or reduced their stakes in the company. Sachetta LLC increased its stake in Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 10 shares during the period. Stephens Consulting LLC purchased a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at about $26,000. Crewe Advisors LLC purchased a new position in Regeneron Pharmaceuticals during the 1st quarter valued at about $28,000. Lynx Investment Advisory purchased a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at about $33,000. Finally, Family Firm Inc. purchased a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at about $33,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $762.00 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $750.20 and a 12-month high of $1,211.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $83.74 billion, a PE ratio of 18.86, a P/E/G ratio of 2.86 and a beta of 0.15. The firm has a 50 day moving average of $977.55 and a two-hundred day moving average of $1,033.65.

Wall Street Analysts Forecast Growth

A number of research firms have commented on REGN. JPMorgan Chase & Co. cut their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research report on Thursday, October 24th. Citigroup began coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, November 14th. They set a “neutral” rating and a $895.00 target price on the stock. Piper Sandler cut their target price on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Guggenheim raised their price target on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Finally, Royal Bank of Canada lowered their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $1,099.55.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This trade represents a 27.07 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 7.48% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.